In the group receiving anthracyclines, HER2-targeted therapy, VEGF inhibitors, or myeloma treatment (n = 347), CVD incidence over the median 7.0 [2.1-12.2] years was highest in the highest HFA-ICOS risk categories (3% in low risk, 17% in moderate risk, and 21% in high/very high risk) (Supplemental Figure 6). Here, ERBB2 is linked to plasma cell myeloma.